Last month, letters were sent regarding ketoconazole HRA and radium-223 dichloride (Xofigo).
In each issue of Drug Safety Update we summarise drug safety letters sent to healthcare professionals that are not linked to their own Drug Safety Update article. In March 2015, letters were sent regarding:
.Ketoconazole HRA: information about the risk of hepatotoxicity – sent by HRA Pharma on 24 March 2015
Radium-223 dichloride (Xofigo▼): change in NIST Standard Reference Material – sent by Bayer on 19 March 2015
Article citation: Drug Safety Update volume 8 issue 9 April 2015: 4